Drug repositioning based on the heterogeneous information fusion graph convolutional network

Abstract

In silico reuse of old drugs (also known as drug repositioning) to treat common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked drugs, with potentially lower overall development costs and shorter development timelines. Therefore, there is a pressing need for computational drug repurposing methodologies to facilitate drug discovery. In this study, we propose a new method, called DRHGCN (Drug Repositioning based on the Heterogeneous information fusion Graph Convolutional Network), to discover potential drugs for a certain disease. To make full use of different topology information in different domains (i.e. drug–drug similarity, disease–disease similarity and drug–disease association networks), we first design inter- and intra-domain feature extraction modules by applying graph convolution operations to the networks to learn the embedding of drugs and diseases, instead of simply integrating the three networks into a heterogeneous network. Afterwards, we parallelly fuse the inter- and intra-domain embeddings to obtain the more representative embeddings of drug and disease. Lastly, we introduce a layer attention mechanism to combine embeddings from multiple graph convolution layers for further improving the prediction performance. We find that DRHGCN achieves high performance (the average AUROC is 0.934 and the average AUPR is 0.539) in four benchmark datasets, outperforming the current approaches. Importantly, we conducted molecular docking experiments on DRHGCN-predicted candidate drugs, providing several novel approved drugs for Alzheimer’s disease (e.g. benzatropine) and Parkinson’s disease (e.g. trihexyphenidyl and haloperidol).

Multilevel threshold image segmentation for COVID-19 chest radiography: A framework using horizontal and vertical multiverse optimization

“…Additionally, the distinct search and exploitation curves demonstrate that the search and exploitation effects of CCMVO are substantially greater than those of MVO. Owing to the strong optimization capability, the CCMVO can also be integrated with the machine learning techniques to tackle the real-world problems such as disease module identification [ 132 , 133 ], drug-disease associations prediction [ 134 ], drug discovery [ 135 , 136 ], pharmacoinformatic data mining [ 137 , 138 ], information retrieval services [ [139] , [140] , [141] ], text clustering [ 142 ], and recommender system [ 143 , 144 ].…”

Boosted Sine Cosine Algorithm with Application to Medical Diagnosis

“…These all proved the robustness and stableness of the ESCA_PSO-SVM on the Cleveland heart problem. Shortly, many problems are waiting to be optimized for which ESCA_PSO can be applied, such as disease module identification [ 66 ], molecular signatures identification for cancer diagnosis [ 67 ], drug-disease associations prediction [ 68 ], drug discovery [ 69 ], and pharmacoinformatic data mining [ 70 ].…”

A Review of Approaches for Predicting Drug–Drug Interactions Based on Machine Learning

“…Deep learning can automatically extract the characteristics of drugs from a dataset and conduct autonomous learning through a multi-layer network to predict unknown DDI. As an artificial neural network with multiple processing layers, DNN can be used to learn highly abstract expressions (Cheng et al, 2018;Su et al, 2019b;Wang et al, 2020a;Cai et al, 2020;Jia et al, 2020;Li et al, 2020;Zhu et al, 2020;Cai et al, 2021;Jin et al, 2021;Liu Q et al, 2021;Su et al, 2021;Zhao et al, 2021). To predict unknown DDI, DNN-based approaches often build a framework using a DNN generated from a variety of drug data.…”